UF Health Cancer Center Oncology Grand Rounds
Presents

“From worst prognosis to best diagnosis:
How targeted therapy has changed the natural history of HER2-driven breast cancer and how the field is continuing to evolve”

Sara A. Hurvitz, MD
Director, Breast Cancer Clinical Research Program
Co-Director, Santa Monica – UCLA Outpatient
Hematology/Oncology Practice
Associate Professor of Medicine, Division of
Hematology/Oncology,
David Geffen School of Medicine
University of California, Los Angeles

Wednesday, May 6, 2020
12:00 – 1:00 pm
Via ZOOM

Register via Zoom: https://uflphi.zoom.us/meeting/register/tJEud-ygrj8qVbfZ3U-PL2jE1Sw9uH40cg

LEARNING OBJECTIVES:

Upon completion of this activity, participants should be able to:

1. Describe major advances in the management of HER2-positive breast cancer of all stages and explain how these therapies have affected long term outcomes for patients.
2. Apply efficacy and safety data from recent trials of newly approved HER2-targeted therapies in the neoadjuvant, adjuvant and metastatic setting and recognize novel therapies currently under investigation.
3. Describe the rationale, as well as early efficacy and safety data associated with combining HER2-targeted therapies with other molecularly targeted therapies.

Speaker Disclosure:
Dr. Hurvitz has disclosed that she has received grant/research support from Ambrx, Amgen, Arvinas, Bayer, Daiichi-Sankyo, Genen/Roche, GSK, Immunomedics, Lilly, Macrogenics, Novartis, Pfizer, OBI Pharma, Pieris, PUMA, Radius, Sanofi, Seattle Genetics, and Dignitana; and other financial or material support for writing/editorial support from the previously mentioned companies for publications related to research. No one else in a position to control content has any financial relationship(s) to disclose.

Accreditation: The University of Florida, College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit: The University of Florida College of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Section # 0257, 0258